Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-012231
Filing Date
2024-08-14
Accepted
2024-08-14 16:10:35
Documents
91
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cara-20240630x10q.htm   iXBRL 10-Q 2625400
2 EX-31.1 cara-20240630xex31d1.htm EX-31.1 12308
3 EX-31.2 cara-20240630xex31d2.htm EX-31.2 11348
4 EX-32.1 cara-20240630xex32d1.htm EX-32.1 11213
  Complete submission text file 0001558370-24-012231.txt   10145758

Data Files

Seq Description Document Type Size
5 EX-101.SCH cara-20240630.xsd EX-101.SCH 66800
6 EX-101.CAL cara-20240630_cal.xml EX-101.CAL 57317
7 EX-101.DEF cara-20240630_def.xml EX-101.DEF 303628
8 EX-101.LAB cara-20240630_lab.xml EX-101.LAB 528912
9 EX-101.PRE cara-20240630_pre.xml EX-101.PRE 458132
94 EXTRACTED XBRL INSTANCE DOCUMENT cara-20240630x10q_htm.xml XML 1805304
Mailing Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901
Business Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901 203-406-3700
Cara Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36279 | Film No.: 241207780
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)